Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population

Berman, Julia; Furer, Victoria; Berman, Mark; Isakov, Ofer; Zisman, Devy; Haddad, Amir; Elkayam, Ori

doi:10.2147/btt.s326792

Cited by 9 publications

(12 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[15][16][17][18] Quite logically, more detailed data about the strategy of use and success rates of individual biologics within the class of IL-17 and IL-23 inhibitors and between both classes are lacking; in fact, only real-world experience from case series or individual case reports is available. [8][9][10][11] Although the efficacy of the newest generations of biologics, as assessed by percentages of achieving target PASI responses, tends to increase, primary resistance and secondary inefficiency developing over time do occur in this class of drugs.…”

Section: Discussionmentioning

confidence: 99%

“…Most data related to the newest generation of biologics (IL‐17 and IL‐23 inhibitors) come from clinical trials assessing their efficacy as first or another line of therapy following failure of the TNF alfa inhibitors or ustekinumab, medicines used in clinical practice for a number of years 15–18 . Quite logically, more detailed data about the strategy of use and success rates of individual biologics within the class of IL‐17 and IL‐23 inhibitors and between both classes are lacking; in fact, only real‐world experience from case series or individual case reports is available 8–11 . Although the efficacy of the newest generations of biologics, as assessed by percentages of achieving target PASI responses, tends to increase, primary resistance and secondary inefficiency developing over time do occur in this class of drugs.…”

Section: Discussionmentioning

confidence: 99%

“…In the relevant literature, current experience with the efficacy of switches within the class of IL‐17 inhibitors is available as case reports or case series 8–11 . In case of a failure of IL‐17 drugs a switch to another category of drugs like anti TNF‐alfa or anti IL12/23 seems safe and effective 12 .…”

Section: Introductionmentioning

confidence: 99%

“…In the relevant literature, current experience with the efficacy of switches within the class of IL-17 inhibitors is available as case reports or case series. [8][9][10][11] In case of a failure of IL-17 drugs a switch to another category of drugs like anti TNF-alfa or anti IL12/23 seems safe and effective. 12 Due to the high number of available biologics there is a need of establishing methods to predict the drug efficacy and survival.…”

mentioning

confidence: 99%

See 3 more Smart Citations

Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP )

Tichý

Kojanová

Velacková

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

The IL-17 cytokine family encompasses six different homodimers and heterodimers referred to as IL-17A-F. Due to some differences in the mechanism of IL-17 inhibition, aninsufficient effect of one IL-17 inhibitor does not necessarily imply lack of efficacy of the other agent of the same class. Aim of study was analysis of the success rate of switches among IL-17 inhibitors (secukinumab, ixekizumab, and brodalumab) in patients treated in the Czech Republic. Data were obtained from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Our analysis involved data of a total of 90 patients with severe chronic plaque psoriasis and baseline PASI scores >10 both prior to first-line biological therapy initiation and after switch to another agent of the class of IL-17 inhibitors. The most effective switch was that from secukinumab to brodalumab, with PASI 90 reached by 64.7% and 73.3% of patients at weeks 12 and 24. Among patients switched from secukinumab to ixekizumab target PASI 90 responses were achieved (at weeks 12 and 24) by 41.2% and 55.2% of patients. Among patients switched from ixekizumab to brodalumab target PASI 90 responses were achieved, at the above time points, by 30.8% and 38.5% of patients. Our analysis showed a high success rate of switches from secukinumab to ixekizumab and brodalumab, followed by the ixekizumab-to-brodalumab switch. Importantly, the therapeutic response and success rates of individual switches are independent of the patient's body weight and presence of psoriatis arthritis.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

mentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP )

Tichý

Kojanová

Velacková

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…OM1, OM1, Boston, United States of America; 4 Eli Lilly and Company, Medical Affairs, Indianapolis, United States of America; 5 Università Degli Studi del Molise, 4.Academic Rheumatology Unit, Dipartimento Di Medicina e Scienze, Campobasso, Italy Background: Ixekizumab (IXE), an IL-17A inhibitor, has demonstrated efficacy in clinical trials [1][2][3] but real-world effectiveness (RWE) data are limited. 4 Objectives: To describe changes in disease activity and patient-reported outcomes (PROs) at 6 and 12 months follow-up among psoriatic arthritis (PsA) patients initiating IXE in a routine clinical setting. Methods: This retrospective cohort study included patients from the OM1 PsA Registry (OM1, Boston, MA), a linked electronic medical record and administrative claims dataset with over 50,000 patients.…”

mentioning

confidence: 99%

Pos1016 relationships Between Disease Duration and Radiographic Progression Among Patients With Psoriatic Arthritis Treated With Secukinumab in Future 5

et al. 2022

View full text Add to dashboard Cite

BackgroundFor patients with psoriatic arthritis (PsA), delays in diagnosis and treatment can lead to permanent radiographic damage, even early in the course of disease.1 In the phase 3 FUTURE 5 study (NCT02404350), treatment with secukinumab (SEC) was shown to inhibit progression of structural damage through Week 104 in patients with PsA.2 However, the effect of disease duration on inhibition of radiographic progression by SEC has not been characterized.ObjectivesThis post hoc analysis explored relationships between time since diagnosis (TSD) of ≤1 year vs >1 year and radiographic progression among patients with PsA receiving SEC over 2 years in FUTURE 5.MethodsPatient data from FUTURE 5 were stratified by TSD ≤1 year vs >1 year and analyzed by treatment arm. Through Week 24, patients received SEC 300 or 150 mg with subcutaneous loading dose (LD), SEC 150 mg without LD, or placebo (PBO) (period 1). After Week 24, patients receiving PBO were switched to SEC 300 or 150 mg (period 2), and a protocol amendment allowed those with suboptimal clinical response to SEC 150 mg to escalate to SEC 300 mg after Week 52 per investigator judgment.2 The proportion of patients with no radiographic progression, defined as change from baseline in van der Heijde total modified Sharp score ≤0.0, was analyzed at Weeks 24, 52, and 104. Mean total Sharp score was evaluated at baseline, and mean change from baseline was determined at Weeks 24, 52, and 104.ResultsOf 996 patients with PsA included here, 217 (21.8%) had a TSD ≤1 year and 779 (78.2%) had a TSD >1 year. At baseline, patients with TSD >1 year had greater radiographic damage than patients with TSD ≤1 year as determined by mean total Sharp score (Table 1). As early as Week 24, patients receiving SEC had less radiographic progression than those receiving PBO, regardless of TSD. From Week 24 to Week 104, radiographic progression remained low among all patients receiving SEC, with a trend of least progression among patients randomized to SEC 300 mg at baseline. Regardless of treatment, patients with TSD >1 year had numerically greater radiographic progression than those patients with TSD ≤1 year. Overall, the proportion of patients receiving SEC who did not have any radiographic progression was higher than that of placebo at Week 24 irrespective of TSD, with a trend towards a higher number of non-progressors among those treated with SEC 300 mg (Figure). Patients randomized to SEC 300 mg were the least likely to experience radiographic progression through 52 weeks.Table 1.Baseline Total Sharp Score and Change From Baseline at Weeks 24, 52, and 104 by TSDTotal Sharp scoreTSD ≤1 yearTSD >1 yearPeriod 1SEC 300 mg n = 54SEC 150 mg n = 46SEC 150 mg NL n = 43PBO n = 74SEC 300 mg n = 168SEC 150 mg n = 174SEC 150 mg NL n = 179PBO n = 258Baseline, mean (SD)8.02 (20.77)8.82 (12.06)12.74 (33.67)8.84 (20.42)14.37 (24.17)14.67 (28.01)15.56 (37.52)17.34 (41.21)Week 24 change from baseline, mean (SD)0.05 (0.72)−0.08 (1.40)−0.61 (5.25)0.76 (2.05)0.09 (1.37)0.23 (1.24)0.03 (2.05)0.42 (1.56)Period 2SEC 300 mg* n = 54SEC 150 mg†n = 46SEC 150 mg NL†n = 43PBO ‒ 300 mg n = 40PBO ‒ 150 mg†n = 30SEC 300 mg* n = 168SEC 150 mg†n = 174SEC 150 mg NL†n = 179PBO ‒ 300 mg n = 113PBO ‒ 150 mg†n = 123Week 52 change from baseline, mean (SD)0.05 (0.48)−0.03 (1.22)0.35 (2.25)0.22 (0.70)0.18 (0.75)−0.07 (1.16)0.26 (1.96)0.26 (1.05)0.16 (0.94)0.40 (2.00)Week 104 change from baseline, mean (SD)0.06 (0.63)0.11 (0.99)0.20 (2.71)0.11 (0.68)−0.07 (0.50)0.11 (2.00)0.62 (2.94)0.46 (2.08)0.12 (0.90)0.81 (2.66)NL, no loading dose; PBO, placebo; SEC, secukinumab; TSD, time since diagnosis.* One outlier in the 300-mg dose group was excluded.† Includes patients who received dose escalation to SEC 300 mg after Week 52.ConclusionSEC resulted in low rates of radiographic progression through 2 years of treatment among patients in FUTURE 5, regardless of time since PsA diagnosis.References[1]Haroon M, et al. Ann Rheum Dis. 2015;74:1045-50.[2]Mease P, et al. RMD Open. 2021;7:e001600.AcknowledgementsThis study was funded by Novartis Pharmaceuticals Corporation. Medical writing support was provided by Richard Karpowicz, PhD, CMPP, of Health Interactions, Inc, and was funded by Novartis Pharmaceuticals Corporation. This abstract was developed in accordance with Good Publication Practice (GPP3) guidelines. Authors had full control of the content and made the final decision on all aspects of this publication.Disclosure of InterestsChristopher T. Ritchlin Consultant of: AbbVie, Amgen, Eli Lilly, Janssen, Pfizer, Novartis, Gilead, and UCB, Ana-Maria Orbai Consultant of: Bristol Myers Squibb, Janssen, Lilly, Novartis, Pfizer, and UCB, Grant/research support from: to Johns Hopkins University from AbbVie, Amgen, Celgene, Horizon, Janssen, Lilly, and Novartis, Bhumik Parikh Employee of: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Corine Gaillez Employee of: Novartis Pharma AG, Basel, Switzerland, Xiangyi Meng Employee of: Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA, Philip J Mease Speakers bureau: AbbVie, Amgen, Janssen, Eli Lilly, Novartis, Pfizer, and UCB, Consultant of: AbbVie, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, Galapagos, Gilead, GlaxoSmithKline, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB, Grant/research support from: AbbVie, Amgen, Bristol Myers Squibb, Celgene, Gilead, Janssen, Eli Lilly, Novartis, Pfizer, Sun Pharma, and UCB

show abstract

Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease

et al. 2023

View full text Add to dashboard Cite

Treatment with Ixekizumab Following Secukinumab Failure in Patients with Psoriatic Arthritis: Real-Life Experience from a Resistant Population

Cited by 9 publications

References 31 publications

Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP )

Efficacy of switches within the class of IL ‐17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy ( BIOREP )

Pos1016 relationships Between Disease Duration and Radiographic Progression Among Patients With Psoriatic Arthritis Treated With Secukinumab in Future 5

Ixekizumab therapy following secukinumab inadequate response in psoriatic arthritis: a case series focusing on axial disease

Contact Info

Product

Resources

About